GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists

Ítems similars

• GLYX-13, a NMDA Receptor Glycine-Site Functional Partial Agonist, Induces Antidepressant-Like Effects Without ketamine-like Side Effects
  per: Burgdorf, Jeffrey, et al.
  Publicat: (2013)
• GLYX-13, a NMDA Receptor Glycine-Site Functional Partial Agonist, Induces Antidepressant-Like Effects Without Ketamine-Like Side Effects
  per: Burgdorf, Jeffrey, et al.
  Publicat: (2013)
• The Development of Rapastinel (Formerly GLYX-13); A Rapid Acting and Long Lasting Antidepressant
  per: Moskal, Joseph R., et al.
  Publicat: (2017)
• The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial prefrontal cortex and hippocampus
  per: Burgdorf, Jeffrey, et al.
  Publicat: (2015)
• A NMDA receptor glycine site partial agonist, GLYX-13, that simultaneously enhances LTP and reduces LTD at Schaffer collateral-CA1 synapses in hippocampus
  per: Zhang, Xiao-lei, et al.
  Publicat: (2008)